Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment Document date: 2020_3_9
ID: 2w0zr9c0_39
Snippet: CoV-2 infection likely impacts its ability to inhibit the IFN-I response and eventual STAT1 231 activation. Similarly, while NSP3 deubiquitinating domain remains intact, SARS-CoV-2 has a 24 232 AA insertion upstream of this deubiquitinating domain that could potentially alter that function 233 (30). While other antagonists are maintained with high levels of conservation (>90%), single 234 point mutations in key locations could modify function and.....
Document: CoV-2 infection likely impacts its ability to inhibit the IFN-I response and eventual STAT1 231 activation. Similarly, while NSP3 deubiquitinating domain remains intact, SARS-CoV-2 has a 24 232 AA insertion upstream of this deubiquitinating domain that could potentially alter that function 233 (30). While other antagonists are maintained with high levels of conservation (>90%), single 234 point mutations in key locations could modify function and contribute to increased IFN 235 sensitivity. Overall, the sequence analysis suggests that differences between SARS-CoV and 236 SARS-CoV-2 viral proteins may drive attenuation in the context of type I IFN pretreatment. 237
Search related documents:
Co phrase search for related documents- conservation high level and sequence analysis: 1
- function modify and IFN response: 1, 2
- function modify and viral protein: 1
- high level and IFN pretreatment: 1
- high level and IFN response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- high level and key location: 1, 2
- high level and SARS viral protein: 1
- high level and sequence analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- high level and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- IFN pretreatment and SARS viral protein: 1
- IFN pretreatment and viral protein: 1, 2, 3, 4, 5
- IFN response and intact remain: 1
- IFN response and SARS viral protein: 1
- IFN response and sequence analysis: 1, 2, 3, 4, 5
- IFN response and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54
- intact remain and viral protein: 1, 2, 3
- SARS viral protein and sequence analysis: 1, 2, 3
- SARS viral protein and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- sequence analysis and viral protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61
Co phrase search for related documents, hyperlinks ordered by date